Prothena
Prothena® Corporation PLC is a late-stage clinical biotechnology company with expertise
in protein dysregulation. Fueled by a deep scientific expertise built over decades of
research, Prothena combines its expertise in protein dysregulation and rigorous scientific
approach to develop therapeutic candidates with best-in-class potential. The pipeline of
investigational therapeutics at Prothena has the potential to change the course of
devastating neurodegenerative and rare peripheral amyloid diseases, diseases which
affect millions of people and their families worldwide.